Helius Medical Technologies Expands Access for PoNS Device
Helius Medical Technologies Broadens Reimbursement Opportunities
Helius Medical Technologies, Inc. (Nasdaq: HSDT), a pioneering company in the neurotech arena, has made significant strides with its Portable Neuromodulation Stimulator (PoNS) Device. The recent news of Aetna authorizing a claim for payment at an out-of-network negotiated price of $18,350 is pivotal. This makes Aetna the third major payer to support reimbursement for the PoNS Device, joining Anthem and United in this effort.
Key Developments in Reimbursement
The authorization of this claim is more than just a financial transaction; it signals a shift towards greater accessibility for individuals dealing with multiple sclerosis (MS). As emphasized by Dane Andreeff, President and CEO of Helius, these reimbursement approvals are milestones for the entire MS community. The company is focused on pursuing broader in-network coverage to secure payment for the PoNS Device at its list price. Current strategies include negotiating on a case-by-case basis, increasing patient access to this transformative technology.
Understanding the PoNS Device and Its Applications
The Portable Neuromodulation Stimulator is an innovative therapy designed to provide neurostimulation through a mouthpiece. It is primarily meant to enhance rehabilitation efforts for individuals suffering from balance and gait deficits. The unique aspect of the PoNS Device is how it delivers mild electrical impulses to the tongue, which works to improve motor functions in conjunction with physical rehabilitation exercises.
Effectiveness in Clinical Settings
Clinical studies have demonstrated the effectiveness of the PoNS Device in treating gait deficits. In Canada, it has received approval for three specific indications: as a short-term treatment for gait deficit due to MS, chronic balance deficits from traumatic brain injury, and for stroke rehabilitation. These endorsements underscore the potential of PoNS therapy not just for MS patients but for a broader range of neurological conditions.
Impact on Patients and Healthcare Systems
This authorization by Aetna is just the first step in what Helius hopes will be a more comprehensive approach to reimbursement across various healthcare systems. The out-of-network payment typically represents 30 to 40% below in-network rates. Patients may face challenges such as high deductibles and out-of-pocket expenses, complicating immediate accessibility to the PoNS Device. Nevertheless, Helius remains committed to exploring avenues that will allow more patients access to this life-changing technology.
Commitment to Continuous Improvement
As Helius expands its reach in the marketplace, the company is determined to negotiate fairer reimbursement rates that align with those offered by the VA/DoD, which is currently set at $26,228. The aim is to ensure that all individuals suffering from neurological disorders can benefit from PoNS therapeutic interventions. In conjunction with these efforts, Helius is also focused on aiding those who rely on Medicare for treatment, striving for improved reimbursements through expanded coverage decisions.
Looking Toward the Future of Neurotechnology
Helius Medical Technologies is dedicated to enhancing the lives of people with neurological diseases by providing innovative solutions. With the PoNS Device at the forefront, the company continues to build upon its platform that utilizes non-invasive technology to stimulate neural responses. This not only aids in rehabilitation but also fosters neuroplasticity, allowing the brain to adapt and recover in ways previously unimagined.
Conclusion: A Step Forward in Neurorehabilitation
The recent developments with Aetna represent a crucial advancement in the accessibility of Helius’ PoNS Device. Continued collaborations with major healthcare providers reflect a growing recognition of the importance of innovative neurotechnology in improving therapeutic outcomes for patients. Helius Medical Technologies is fully committed to advancing its mission and exploring new pathways to help individuals manage their neurological health effectively.
Frequently Asked Questions
What is the PoNS Device?
The Portable Neuromodulation Stimulator is a device that provides neurostimulation through a mouthpiece to help improve balance and gait in patients with neurological disorders.
Who is Helius Medical Technologies?
Helius Medical Technologies, Inc. is a neurotechnology company that focuses on developing innovative products to support individuals with neurological deficits.
What recent development has Helius announced?
Helius announced that Aetna has authorized a claim for reimbursement for the PoNS Device, expanding access for patients.
How is the PoNS Device used in treatment?
It is used at home in conjunction with physical rehabilitation exercises to improve motor functions in individuals.
What are the next steps for Helius regarding reimbursement?
Helius aims to secure broader in-network coverage and negotiate reimbursements that align with what is offered by other healthcare systems.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
